HGH and Orforglipron Interaction: Monitor | Peptide Database

Join others researching Halotestin — share findings, ask questions, and learn from real experiences Halotestin (fluoxymesterone) is a synthetic oral anabolic-androgenic steroid derived from testosterone, first introduced in the late 1950s by Upjohn under the brand name Halotestin. It is characterized by an extraordinarily high androgenic rating of approximately 1900 relative to testosterone, paired with an anabolic rating of roughly 1900 as well, though its real-world muscle-building effects are far less pronounced than these numbers suggest. The compound was originally FDA-approved for the treatment of male hypogonadism and advanced breast cancer in women, though it is rarely prescribed today due to the availability of safer alternatives. Fluoxymesterone does not aromatize to estrogen, meaning it produces no estrogenic side effects such as water retention or gynecomastia. In performance contexts, halotestin is used almost exclusively by advanced athletes and competitive bodybuilders in the final weeks before competition or powerlifting meets, where its ability to dramatically increase aggression, neural drive, and strength output without adding water weight makes it uniquely valuable. It is considered one of the harshest oral steroids with respect to hepatotoxicity and is unsuitable for general physique enhancement or beginner use. Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue. The compound's performance-enhancing effects are largely mediated through the central nervous system, increasing aggression, motivation, and perceived energy through androgen receptor activation in the brain. Fluoxymesterone also stimulates erythropoietin production, increasing red blood cell mass and oxygen-carrying capacity, which was the basis for its historical use in treating certain anemias. It enhances hemoglobin synthesis and may improve muscular endurance through improved oxygen delivery. The 17-alpha-methylation allows oral bioavailability but imposes significant hepatic stress, as the liver must process the intact steroid through first-pass metabolism. Fluoxymesterone suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis, and its extreme androgenic load can rapidly affect mood, lipid profiles, and prostate tissue.

Meta-analyses show modest cognitive improvements, though clinical significance remains debated. Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements. Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit. Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement. Multiple trials including CAPTAIN series confirm GCS/GOS improvements. Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies. Some studies show enhanced recovery; results vary significantly between trials. Early administration within 72 hours shows better outcomes than delayed treatment.